Enhanced cell-associated plasminogen activator pathway but not coagulation pathway activity contributes to motility in metastatic breast cancer cells

Journal of Thrombosis and Haemostasis

Volumn 8, Issue 6, 2010, Pages 1323-1332

  Carter, J C ^a,b   Campbell, R A ^a,c   Gibbons, J A ^a,d   Gramling, M W ^a   Wolberg, A S ^a   Church, F C ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b VANDERBILT UNIVERSITY   (United States)

^c UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^d SABiosciences Corporation   (United States)

Author keywords

Breast cancer; Cell motility; Plasminogen activator inhibitor 1; Thrombin; Urokinase

Indexed keywords

AMILORIDE; BLOOD CLOTTING FACTOR 10A; FIBRIN; MESSENGER RNA; PLASMIN; PLASMINOGEN ACTIVATOR; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN KINASE B; PROUROKINASE; THROMBIN;

ARTICLE; BLOOD CLOT LYSIS; BLOOD CLOTTING; BREAST CANCER; CELL MOTILITY; CELL SURFACE; CELL TYPE; CONTROLLED STUDY; CYTOLYSIS; ENZYME ACTIVITY; ENZYME SYNTHESIS; FEMALE; FIBRIN FORMATION; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; MALE; METASTASIS; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION;

BASE SEQUENCE; BLOOD COAGULATION; BREAST NEOPLASMS; CELL LINE, TUMOR; DNA PRIMERS; FEMALE; HUMANS; NEOPLASM METASTASIS; PLASMINOGEN ACTIVATORS; PREGNANCY;

EID: 77954511710     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2010.03825.x     Document Type: Article

References (56)

1. Bick RL. Cancer-associated thrombosis. N Engl J Med 2003, 349:109-11.
2. Bromberg ME, Konigsberg WH, Madison JF, Pawashe A, Garen A. Tissue factor promotes melanoma metastasis by a pathway independent of blood coagulation. Proc Natl Acad Sci USA 1995, 92:8205-9.
3. Mueller BM, Reisfeld RA, Edgington TS, Ruf W. Expression of tissue factor by melanoma cells promotes efficient hematogenous metastasis. Proc Natl Acad Sci USA 1992, 89:11832-6.
4. Pawlinski R, Mackman N. Use of mouse models to study the role of tissue factor in tumor biology. Semin Thromb Hemost 2008, 34:182-6.
5. Dano K, Andreasen PA, Grondahl-Hansen J, Kristensen P, Nielsen LS, Skriver L. Plasminogen activators, tissue degradation, and cancer. Adv Cancer Res 1985, 44:139-266.
6. Beaulieu LM, Whitley BR, Wiesner TF, Rehault SM, Palmieri D, Elkahloun AG, Church FC. Breast cancer and metabolic syndrome linked through the plasminogen activator inhibitor-1 cycle. Bioessays 2007, 29:1029-38.
7. Carter JC, Church FC. Obesity and breast cancer: the roles of peroxisome proliferator-activated receptor-gamma and plasminogen activator inhibitor-1. PPAR Res 2009, 2009:345320.
8. Wolberg AS, Campbell RA. Thrombin generation, fibrin clot formation and hemostasis. Transfus Apher Sci 2008, 38:15-23.
9. Mackman N. The many faces of tissue factor. J Thromb Haemost 2009, 7(Suppl. 1):136-9.
10. Ruf W. Tissue factor and PAR signaling in tumor progression. Thromb Res 2007, 2:S7-12.
11. Schaffner F, Ruf W. Tissue factor and PAR2 signaling in the tumor microenvironment. Arterioscler Thromb Vasc Biol 2009, 29:1999-2004.
12. Crago AM, Wu HF, Hoffman M, Church FC. Monocyte chemoattractant activity of Ser195→Ala active site mutant recombinant alpha-thrombin. Exp Cell Res 1995, 219:650-6.
13. Rak J, Yu JL, Luyendyk J, Mackman N. Oncogenes, trousseau syndrome, and cancer-related changes in the coagulome of mice and humans. Cancer Res 2006, 66:10643-6.
14. Andreasen PA, Egelund R, Petersen HH. The plasminogen activation system in tumor growth, invasion, and metastasis. Cell Mol Life Sci 2000, 57:25-40.
15. Binder BR, Mihaly J. The plasminogen activator inhibitor 'paradox' in cancer. Immunol Lett 2008, 118:116-24.
16. Booth NA. Fibrinolysis and thrombosis. Baillieres Best Pract Res Clin Haematol 1999, 12:423-33.
17. Grondahl-Hansen J, Christensen IJ, Rosenquist C, Brunner N, Mouridsen HT, Dano K, Blichert-Toft M. High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis. Cancer Res 1993, 53:2513-21.
18. Knoop A, Andreasen PA, Andersen JA, Hansen S, Laenkholm AV, Simonsen AC, Andersen J, Overgaard J, Rose C. Prognostic significance of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 in primary breast cancer. Br J Cancer 1998, 77:932-40.
19. Dawson PJ, Wolman SR, Tait L, Heppner GH, Miller FR. MCF10AT: a model for the evolution of cancer from proliferative breast disease. Am J Pathol 1996, 148:313-19.
20. Santner SJ, Dawson PJ, Tait L, Soule HD, Eliason J, Mohamed AN, Wolman SR, Heppner GH, Miller FR. Malignant MCF10CA1 cell lines derived from premalignant human breast epithelial MCF10AT cells. Breast Cancer Res Treat 2001, 65:101-10.
21. MacDonald NJ, Freije JM, Stracke ML, Manrow RE, Steeg PS. Site-directed mutagenesis of nm23-H1. Mutation of proline 96 or serine 120 abrogates its motility inhibitory activity upon transfection into human breast carcinoma cells. J Biol Chem 1996, 271:25107-16.
22. Luddington R, Baglin T. Clinical measurement of thrombin generation by calibrated automated thrombography requires contact factor inhibition. J Thromb Haemost 2004, 2:1954-9.
23. Machlus KR, Colby EA, Wu JR, Koch GG, Key NS, Wolberg AS. Effects of tissue factor, thrombomodulin, and elevated clotting factor levels on thrombin generation in the calibrated automated thrombogram. Thromb Haemost 2009, 102:936-44.
24. Wolberg AS, Monroe DM, Roberts HR, Hoffman MR. Tissue factor de-encryption: ionophore treatment induces changes in tissue factor activity by phosphatidylserine-dependent and -independent mechanisms. Blood Coagul Fibrinolysis 1999, 10:201-10.
25. Carson SD, Ross SE, Bach R, Guha A. An inhibitory monoclonal antibody against human tissue factor. Blood 1987, 70:490-3.
26. Hemker HC, Giesen P, Al Dieri R, Regnault V, de Smedt E, Wagenvoord R, Lecompte T, Beguin S. Calibrated automated thrombin generation measurement in clotting plasma. Pathophysiol Haemost Thromb 2003, 33:4-15.
27. Campbell RA, Overmyer KA, Bagnell CR, Wolberg AS. Cellular procoagulant activity dictates clot structure and stability as a function of distance from the cell surface. Arterioscler Thromb Vasc Biol 2008, 28:2247-54.
28. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 2001, 25:402-8.
29. Whitley BR, Palmieri D, Twerdi CD, Church FC. Expression of active plasminogen activator inhibitor-1 reduces cell migration and invasion in breast and gynecological cancer cells. Exp Cell Res 2004, 296:151-62.
30. Nielsen LS, Hansen JG, Skriver L, Wilson EL, Kaltoft K, Zeuthen J, Dano K. Purification of zymogen to plasminogen activator from human glioblastoma cells by affinity chromatography with monoclonal antibody. Biochemistry 1982, 21:6410-15.
31. Mussoni L, Lawrence D, Loskutoff DJ. A direct, plasmin-independent assay for plasminogen activator. Thromb Res 1984, 34:241-54.
32. Fischer EG, Ruf W, Mueller BM. Tissue factor-initiated thrombin generation activates the signaling thrombin receptor on malignant melanoma cells. Cancer Res 1995, 55:1629-32.
33. Shigemori C, Wada H, Matsumoto K, Shiku H, Nakamura S, Suzuki H. Tissue factor expression and metastatic potential of colorectal cancer. Thromb Haemost 1998, 80:894-8.
34. Dupont DM, Madsen JB, Kristensen T, Bodker JS, Blouse GE, Wind T, Andreasen PA. Biochemical properties of plasminogen activator inhibitor-1. Front Biosci 2009, 14:1337-61.
35. Kietzmann T, Andreasen P. Plasminogen activator inhibitor-1 (PAI-1): a molecule at the crossroads to cell survival or cell death. Thromb Haemost 2008, 100:965-8.
36. Vassalli JD, Belin D. Amiloride selectively inhibits the urokinase-type plasminogen activator. FEBS Lett 1987, 214:187-91.
37. Towle MJ, Lee A, Maduakor EC, Schwartz CE, Bridges AJ, Littlefield BA. Inhibition of urokinase by 4-substituted benzo[b]thiophene-2-carboxamidines: an important new class of selective synthetic urokinase inhibitor. Cancer Res 1993, 53:2553-9.
38. Whitley BR, Beaulieu LM, Carter JC, Church FC. Phosphatidylinositol 3-kinase/Akt regulates the balance between plasminogen activator inhibitor-1 and urokinase to promote migration of SKOV-3 ovarian cancer cells. Gynecol Oncol 2007, 104:470-9.
39. Kwaan HC, Wang J, Svoboda K, Declerck PJ. Plasminogen activator inhibitor 1 may promote tumour growth through inhibition of apoptosis. Br J Cancer 2000, 82:1702-8.
40. LeBedis C, Chen K, Fallavollita L, Boutros T, Brodt P. Peripheral lymph node stromal cells can promote growth and tumorigenicity of breast carcinoma cells through the release of IGF-I and EGF. Int J Cancer 2002, 100:2-8.
41. Sun H, Berquin IM, Edwards IJ. Omega-3 polyunsaturated fatty acids regulate syndecan-1 expression in human breast cancer cells. Cancer Res 2005, 65:4442-7.
42. Belkacemi L, Lam E, Caldwell JD, Siemens DR, Graham CH. Stimulation of human breast carcinoma cell invasiveness and urokinase plasminogen activator activity by glucose deprivation. Exp Cell Res 2006, 312:1685-92.
43. Campbell RA, Overmyer KA, Selzman CH, Sheridan BC, Wolberg AS. Blood 2009, 114:4886-96.
44. Botteri FM, Ballmer-Hofer K, Rajput B, Nagamine Y. Disruption of cytoskeletal structures results in the induction of the urokinase-type plasminogen activator gene expression. J Biol Chem 1990, 265:13327-34.
45. Kirchheimer JC, Wojta J, Christ G, Binder BR. Proliferation of a human epidermal tumor cell line stimulated by urokinase. FASEB J 1987, 1:125-8.
46. Wei Y, Waltz DA, Rao N, Drummond RJ, Rosenberg S, Chapman HA. Identification of the urokinase receptor as an adhesion receptor for vitronectin. J Biol Chem 1994, 269:32380-8.
47. Kanse SM, Kost C, Wilhelm OG, Andreasen PA, Preissner KT. The urokinase receptor is a major vitronectin-binding protein on endothelial cells. Exp Cell Res 1996, 224:344-53.
48. Edwards S, Lalor PF, Tuncer C, Adams DH. Vitronectin in human hepatic tumours contributes to the recruitment of lymphocytes in an alpha v beta3-independent manner. Br J Cancer 2006, 95:1545-54.
49. Fazioli F, Resnati M, Sidenius N, Higashimoto Y, Appella E, Blasi F. A urokinase-sensitive region of the human urokinase receptor is responsible for its chemotactic activity. EMBO J 1997, 16:7279-86.
50. Rodriguez-Viciana P, Warne PH, Vanhaesebroeck B, Waterfield MD, Downward J. Activation of phosphoinositide 3-kinase by interaction with Ras and by point mutation. EMBO J 1996, 15:2442-51.
51. Wang MH, Montero-Julian FA, Dauny I, Leonard EJ. Requirement of phosphatidylinositol-3 kinase for epithelial cell migration activated by human macrophage stimulating protein. Oncogene 1996, 13:2167-75.
52. Shukla S, Maclennan GT, Hartman DJ, Fu P, Resnick MI, Gupta S. Activation of PI3K-Akt signaling pathway promotes prostate cancer cell invasion. Int J Cancer 2007, 121:1424-32.
53. Niers TM, Bruggemann LW, Vans GL, Liu RD, Versteeg HH, Buller HR, Vann CJ, Reitsma PH, Spek CA, Richel DJ. Long-term thrombin inhibition promotes cancer cell extravasation in a mouse model of experimental metastasis. J Thromb Haemost 2009, 7:1595-7.
54. Douketis JD, Gu C, Piccioli A, Ghirarduzzi A, Pengo V, Prandoni P. The long-term risk of cancer in patients with a first episode of venous thromboembolism. J Thromb Haemost 2009, 7:546-51.
55. Meyer JE, Brocks C, Graefe H, Mala C, Thäns N, Bürgle M, Rempel A, Rotter N, Wollenberg B, Lang S. The oral serine protease inhibitor WX-671 - first experience in patients with advanced head and neck carcinoma. Breast Care 2008, 3(Suppl. 2):20-4.
56. Goldstein LJ. Experience in phase I trials and an upcoming phase II study with uPA inhibitors in metastatic breast cancer. Breast Care 2008, 3(Suppl. 2):25-8.